Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

New England Journal of Medicine

Volumn 352, Issue 10, 2005, Pages 987-996

  Stupp, Roger ^a   Mason, Warren P ^b   Van Den Bent, Martin J ^c   Weller, Michael ^d   Fisher, Barbara ^e   Taphoorn, Martin J B ^f   Belanger, Karl ^g   Brandes, Alba A ^h   Marosi, Christine ⁱ   Bogdahn, Ulrich ^j   Curschmann, Jürgen ^k   Janzer, Robert C ^a   Ludwin, Samuel K ^l   Gorlia, Thierry ^m   Allgeier, Anouk ^m   Lacombe, Denis ^m   Cairncross, J Gregory ⁿ   Eisenhauer, Elizabeth ^o   Mirimanoff, René O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g NOTRE DAME HOSPITAL   (Canada)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k UNIVERSITY OF BERN   (Switzerland)

^l QUEEN S UNIVERSITY   (Canada)

^m Cancer Data Center   (Belgium)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o Queen's Cancer Research Institute   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; METOCLOPRAMIDE; PENTAMIDINE; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; DISEASE COURSE; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, COMPUTER-ASSISTED; SURVIVAL ANALYSIS;

EID: 20044366163     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043330     Document Type: Article

References (36)

1. Euckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30:Suppl 19:10-4.
2. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
3. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
4. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial. J Neurosurg 1978;49: 333-43.
5. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
6. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-32.
7. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: a joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007.
8. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group trial 8001. J Neurosurg 1989;71:1-9.
9. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001;19:509-18.
10. Stupp R, Hegi MB. Recent developments in the management of malignant glioma. In: Perry MC, ed. ASCO 2003 educational book. Alexandria, Va.: American Society of Clinical Oncology, 2003:779-88.
11. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
12. Newlands BS, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
13. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2:552-60.
14. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83: 588-93.
15. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
16. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11.
17. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-4. [Erratum, N Engl J Med 2000;343: 1740.]
18. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-4. [Erratum, N Engl J Med 2000;343: 1740.]
19. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
20. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
21. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
22. Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981: NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer 2004;40:1724-30.
23. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000;342:1416-29.
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase n studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
25. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Vol. 1 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2000.
26. Shapiro WR. Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol 1992;148:428-34.
27. Grossman SA, O'Neill A, Grannet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003;21: 1485-91.
28. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1999;16:1389-96.
29. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79-88.
30. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16: 3851-7.
31. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
32. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997;8:92-7.
33. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
34. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002;62:1915-9.
35. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-36.
36. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.